New CAR t therapy targets two proteins to fight blood cancers
NCT ID NCT07166549
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a new type of CAR T cell therapy that targets two proteins (CD19 and CD20) on B cell cancer cells. It is for adults with B cell leukemia or lymphoma who have run out of standard options, including commercial CAR T cells. The main goal is to check safety, but researchers will also look at how well the treatment shrinks tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- bispecific anti-CD19, anti-CD20 CAR T cells
- What this could lead to
- If this works, it could offer a new treatment option for people with B cell cancers that have not responded to other therapies, including commercial CAR T cells.
- What could go wrong
- This is a very early phase 1 trial with only 12 participants, so it is too soon to know if it is safe or effective. There are known risks like cytokine release syndrome and neurological side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Hospital Basel, Division of Hematology or Medical Oncology
Basel, Canton of Basel-City, 4031, Switzerland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can antibody infusions outperform antibiotics in shielding CAR-T patients from infections?
- Engineered immune cells take aim at tough childhood leukemia
- Double-Targeted immune cells take aim at Hard-to-Treat blood cancers
- Double-Pronged immune cells take aim at blood cancers
- Double-Pronged CAR-T cells take aim at Hard-to-Treat blood cancers
- Scientists build a biobank to crack the mystery of CAR-T cell failure